VYGR
Voyager Therapeutics Inc
2.70$
-4.3%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 72.7% | 85.4% | 94.3% | 93.1% | 91.8% | 85.9% | 75.6% | 70.5% | 78.1% | 91.0% | 70.4% | 80.3% | |
| 61.2% | 13.6% | 19.3% | 17.1% | 26.5% | 24.3% | 39.9% | 60.6% | 62.1% | 19.6% | 18.2% | 25.9% | |
| 61.2% | 97.8% | 92.0% | 91.6% | 88.0% | 79.4% | 69.2% | 68.4% | 74.6% | 65.7% | 67.8% | 77.9% | |
| – | 0.2% | 1.2% | 0.1% | 0.1% | 5.3% | 3.1% | 0.4% | 0.4% | 24.0% | 1.1% | 0.7% | |
| – | -12.7% | 0.8% | 1.0% | 2.9% | 0.6% | 2.7% | 0.9% | 0.5% | 0.0% | – | – | |
| 24.4% | 1.4% | 4.2% | 5.6% | 7.2% | 13.1% | 9.7% | 11.3% | 11.2% | – | – | – | |
| – | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| – | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 90.0% | 26.3% | 28.3% | 27.3% | 73.8% | 71.9% | 41.0% | 51.0% | 63.0% | 32.7% | 23.7% | 22.3% | |
| 21.5% | 10.4% | 7.3% | 8.6% | 17.9% | 21.4% | 10.2% | 26.3% | 45.6% | 18.4% | 12.7% | 10.5% | |
| 54.8% | – | – | – | – | 0.9% | 1.6% | 2.9% | 1.8% | 0.9% | 1.8% | 3.1% | |
| 13.5% | 0.3% | 0.3% | 0.6% | 0.6% | 1.1% | 0.2% | 0.3% | 1.6% | 0.5% | 1.0% | 2.0% | |
| 54.8% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 10.0% | 73.7% | 71.7% | 72.7% | 26.2% | 28.1% | 59.0% | 49.0% | 37.0% | 67.3% | 76.3% | 77.7% | |
| -181.2% | -21.7% | -47.5% | -87.1% | -152.0% | -88.1% | -105.5% | -179.1% | -246.9% | -74.4% | -83.0% | -176.7% | |
| 128.0% | 1.8% | 13.3% | 14.5% | 18.1% | 10.1% | 14.3% | 19.4% | 24.1% | 12.7% | 14.7% | 23.3% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.